Essential Partners’s Novavax NVAX Stock Holding History

Essential Partners’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.06K	Buy	856 +832	+3,467%	+$7.46K	﹤0.01%	1320
2026 Q1	$195	Buy	+24	New	+$218	﹤0.01%	2615

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Essential Partners's NVAX Position: Q2 2026 in Review

Essential Partners increased its Novavax (NVAX) stake by 3,467% in Q2 2026, buying an estimated $7.46K and bringing the position to 856 shares worth $8.06K. The position accounts for ﹤0.01% of the portfolio, ranked #1320.

Essential Partners first reported a position in NVAX in Q1 2026 and has held it in 2 quarters since. 268 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

Essential Partners held 856 shares of Novavax worth $8.06K as of Q2 2026.
Essential Partners bought 832 Novavax shares in Q2 2026, an estimated $7.46K.
Novavax made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1320 holding.
Essential Partners first reported a position in Novavax in Q1 2026 and has held it in 2 quarters since.
268 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.